INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 125 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $20,790,000 | +70.6% | 771,427 | -52.9% | 0.22% | -26.3% |
| Q1 2020 | $12,186,000 | -19.5% | 1,637,926 | -64.3% | 0.30% | -20.4% |
| Q4 2019 | $15,130,000 | +74.8% | 4,584,966 | +8.6% | 0.38% | +102.1% |
| Q3 2019 | $8,657,000 | -25.6% | 4,222,690 | +6.8% | 0.19% | -35.5% |
| Q2 2019 | $11,628,000 | +6.4% | 3,955,017 | +35.0% | 0.29% | -6.1% |
| Q1 2019 | $10,927,000 | +44.9% | 2,929,597 | +55.4% | 0.31% | +2.0% |
| Q4 2018 | $7,543,000 | -29.2% | 1,885,641 | -1.6% | 0.31% | -5.0% |
| Q3 2018 | $10,659,000 | +127.6% | 1,917,071 | +60.5% | 0.32% | +87.2% |
| Q2 2018 | $4,683,000 | +49.7% | 1,194,657 | +79.8% | 0.17% | +11.0% |
| Q1 2018 | $3,129,000 | +164.7% | 664,410 | +132.1% | 0.16% | +64.9% |
| Q4 2017 | $1,182,000 | +128.6% | 286,277 | +334.4% | 0.09% | -6.9% |
| Q2 2017 | $517,000 | +112.8% | 65,901 | +79.2% | 0.10% | +44.3% |
| Q1 2017 | $243,000 | +12.0% | 36,773 | +17.8% | 0.07% | -11.4% |
| Q4 2016 | $217,000 | – | 31,226 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |